This trial is evaluating whether Physician Education about Gabapentinoid Prescription will improve 1 primary outcome and 6 secondary outcomes in patients with Pregabalin. Measurement will happen over the course of At study enrollment and 8-weeks post-hospital discharge.
This trial requires 160 total participants across 2 different treatment groups
This trial involves 2 different treatments. Physician Education About Gabapentinoid Prescription is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"A wide number of clinical and veterinary practitioners in Australia have the opportunity to prescribe pregabalin, a licensed gabapentinoid. In the event of an adverse event, the use and appropriate referral of veterinary veterinary assistance is essential." - Anonymous Online Contributor
"In this article, we discuss the role of anion gap, a test commonly used pregabalin monitoring, which has previously been investigated. In the literature regarding anion gap, the major focus has been on assessing anion gap to predict the presence of methanol or ethylene glycol in a patient's blood. The current report is the first to describe a causal association between anion gap and the cause for pregabalin." - Anonymous Online Contributor
"Pregabalin has a number of popular treatment options including long-term daily dosages on an as needed or prn basis, and the use of short-acting prn dosages as an alternative to long-term daily use, and also as a short-term prn option for those who struggle with long-term daily use. Pregabalin is a very effective drug and effective treatment option for the management of fibromyalgia. As its use is expanding this will likely lead to a rise in prescribing, and the potential for a number of other side-effects." - Anonymous Online Contributor
"Pregabalin may improve [chronic pain](https://www.withpower.com/clinical-trials/chronic-pain) in a significant proportion of patients without causing any side effects. However, although the pain relief may be significant for many patients, the number and magnitude may be underestimated once remission is considered. Many patients and clinicians need further information about ongoing and future potential harm to the kidneys and blood pressure." - Anonymous Online Contributor
"While the symptoms were fairly similar to those of the placebo group, the signs of PGP show a difference between the two groups. This difference occurs in the early period of treatment, which could be used as a sign that treatment is working in the patient's body. The difference might be attributable to the difference in dose used in the PGP group. Further research is required to clarify the effectiveness of PGP compared to placebo using the same dose and for a longer period." - Anonymous Online Contributor
"around 20 million people in the United States take the medication prescribed for their pain. The majority (around 50%) of these patients have not had a proper assessment of the pain and are prescribed PGE1 or COX2-inhibiting analgesics. Such patients might feel better in a few days. However, there is no evidence that pregabalin has significant benefit on PGE1 and COX2 inhibitors, and the analgesicity of pregabalin may be only occasional, and not to be considered a main benefit." - Anonymous Online Contributor
"Pregabalin is used extensively in [Pain management clinics], and as a prescription drug, as a consequence for those not already receiving it. It is commonly prescribed and dispensed for a number of indications. However, as a prescription drug, pregabalin may be dispensed for a wider range of conditions than any one single indication. Therefore, a wider age range of people may receive it and for a number of people, the potential side effects of pregabalin may be less severe." - Anonymous Online Contributor
"Data from a recent study of our meta-analysis show that the evidence to support the use of gabapentinoids to reduce neuropathic pain is stronger than any of these potential risk factors. This includes those that were evaluated in terms of the use of gabapentinoids to treat neuropathic pain. Therefore, gabapentinoids can be used for the treatment of chronic neuropathic pain like diabetic neuropathy and peripheral neuropathy. However, gabapentinoids can be used to treat neuropathic pain in multiple other situations, like postherpetic neuralgia (PHN), neuropathic pain due to cancer or stroke, and for treating fibromyalgia." - Anonymous Online Contributor
"The majority of the physicians did not think that the use of gabapentinoids in the management of neuropathic pain is useful and that such non use has little medical rationale. More specific information or even simple guidelines could potentially improve prescribing behavior." - Anonymous Online Contributor
"A small number of patients were referred to a specialty pharmacy because they wanted to avoid prescription drugs; of these patients, gabapentinoids were the drug of choice. Most of the patients continued their doctors' recommendation; a minority of them continued to use nonsteroidal anti-inflammatory drugs. Only seven patients enrolled in the study finished their year: six received gabapentinoid treatment plus nonsteroidal anti-inflammatory drug therapy, one received only nonsteroidal anti-inflammatory drug therapy, and none received placebo. The study failed to show benefit for gabapentinoid therapy (0.97, 95% CI, 0.83 to 1.09), nonsteroidal anti-inflammatory drug therapy (0.83, 0." - Anonymous Online Contributor
"Many physicians use gabapentinoids as part of treatment for DPN, but only one third reported having been informed about these drugs by their prescribing physician. In our study, the willingness and knowledge of physicians to inform patients about gabapentinoid treatment was related to the years' experience, and to a higher degree by neurology versus gastroenterology." - Anonymous Online Contributor
"A clear and consistent understanding of prescribing for people receiving gabapentinoid is important for safety. Patient education and education about gabapentinoids is critical to patient safety." - Anonymous Online Contributor